A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:21 - Any
Updated:10/12/2017
Start Date:August 2014
End Date:August 2021
Contact:William F Fearon, MD
Email:wfearon@stanford.edu
Phone:650-725-2621

Use our guide to learn which trials are right for you!

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary
pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided
percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease
(CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).

The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority
trial. All patients with multivessel CAD (not involving the left main) will be screened by
the site's Heart Team (including but not limited to an interventional cardiologist, cardiac
surgeon and research coordinator). If all agree that the patient can be treated either with
FFR-guided PCI or CABG, and all inclusion criteria are met and no exclusion criteria are met,
then the patient will be randomized.

Baseline clinical, functional, laboratory and electrocardiographic data will be obtained.
Patients will receive treatment within 4 weeks of randomization. Patients randomized to CABG
will receive state of the art therapy at the discretion of the local surgeon with a strong
emphasis on arterial revascularization. Patients undergoing PCI will have FFR measured with a
St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI
will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual
routine. If the FFR is >0.80 then PCI will be deferred.

All patients will receive medical therapy as per published guidelines. Patients will
follow-up at 1 and 6 months, and 1 and 3 years with an evaluation of clinical status,
functional status, medications and events. Follow-up may be extended to 5 years, if funding
allows.

Core lab analyses will include formal quantitative coronary angiography (QCA) of the baseline
angiograms with calculation of the Synergy between Percutaneous Coronary Intervention with
Taxus and Cardiac Surgery (SYNTAX) score and Functional SYNTAX Score.

Inclusion Criteria:

- 1. Age ≥ 21 years with angina and/or evidence of myocardial ischemia

- 2. Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each
of the three major epicardial vessels or major side branches, but not involving left
main coronary artery, and amenable to revascularization by both PCI and CABG as
determined by the Heart Team. Patients with a non-dominant right coronary artery may
be included if only the left anterior descending artery (LAD) and left circumflex have
≥50% stenosis

- 3. Willing and able to provide informed, written consent

Exclusion Criteria:

- 1. Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve
replacement, carotid revascularization)

- 2. Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support

- 3. Recent STEMI (<5 days prior to randomization)

- 4. Ongoing Non STEMI with biomarkers (cardiac troponin) still rising

- 5. Known left ventricular ejection fraction <30%

- 6. Life expectancy < 2 years

- 7. Requiring renal replacement therapy

- 8. Undergoing evaluation for organ transplantation

- 9. Participation or planned participation in another clinical trial, except for
observational registries

- 10. Pregnancy

- 11. Inability to take dual antiplatelet therapy for six months

- 12. Previous CABG

- 13. Left main disease requiring revascularization

- 14. Extremely calcified or tortuous vessels precluding FFR measurement

- 15. Any target lesion with in-stent drug-eluting stent restenosis
We found this trial at
14
sites
740 South Limestone Street
Lexington, Kentucky 40536
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: Michael Ragosta, MD
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Mladen Vidovich, MD
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Kreton Mavromatis, MD
?
mi
from
Decatur, GA
Click here to add this to my saved trials
2 Hastings Road
Frankston, 3199
?
mi
from
Frankston,
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Principal Investigator: Alpesh Shah, MD
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lawrence, Kansas
Principal Investigator: Peter Tadross, MD
?
mi
from
Lawrence, KS
Click here to add this to my saved trials
1101 Veterans Drive
Lexington, Kentucky 40502
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Paul Myers, MD
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: John Giacomini, MD
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania
Principal Investigator: William H Matthai, MD
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Saint Paul, Minnesota 55102
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
759 Chestnut Street
Springfield, Massachusetts 01199
(413) 794 - 0000
Baystate Medical Center Baystate Medical Center (BMC), in Springfield, Massachusetts, is an academic, research, and...
?
mi
from
Springfield, MA
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: William F Fearon, MD
Phone: 650-725-2621
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials